Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Lavaud, Pernelle"'
Autor:
Bigot L; Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Inserm U981, Gustave Roussy Cancer, Université Paris-Saclay, Villejuif, France., Sabio J; Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Inserm U981, Gustave Roussy Cancer, Université Paris-Saclay, Villejuif, France., Poiraudeau L; Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Inserm U981, Gustave Roussy Cancer, Université Paris-Saclay, Villejuif, France., Annereau M; Pharmacy, Gustave Roussy, Université Paris-Saclay, Villejuif, France., Menssouri N; Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Inserm U981, Gustave Roussy Cancer, Université Paris-Saclay, Villejuif, France., Helissey C; Clinical Research Unit, Department of Oncology, Military Hospital Begin, Saint-Mandé, France., Déas O; XenTech, Evry, France., Aglave M; Plateforme de Bioinformatique, Gustave Roussy, Villejuif, France., Ibrahim T; Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Inserm U981, Gustave Roussy Cancer, Université Paris-Saclay, Villejuif, France., Pobel C; Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Inserm U981, Gustave Roussy Cancer, Université Paris-Saclay, Villejuif, France., Nobre C; Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Inserm U981, Gustave Roussy Cancer, Université Paris-Saclay, Villejuif, France., Nicotra C; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France., Ngo-Camus M; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France., Lacroix L; Experimental and Translational Pathology Platform (PETRA), Genomic Platform - Molecular Biopathology Unit (BMO) and Biological Resource Center, AMMICA, INSERM, Villejuif, France; Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France., Rouleau E; Experimental and Translational Pathology Platform (PETRA), Genomic Platform - Molecular Biopathology Unit (BMO) and Biological Resource Center, AMMICA, INSERM, Villejuif, France; Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France., Tselikas L; Department of Interventional Radiology, Gustave Roussy Cancer Campus, Villejuif, France., Judde JG; XenTech, Evry, France., Chauchereau A; Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Inserm U981, Gustave Roussy Cancer, Université Paris-Saclay, Villejuif, France., Bernard-Tessier A; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Patrikidou A; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Naoun N; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Flippot R; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Colomba E; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Fuerea A; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Albiges L; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Lavaud P; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Massard C; Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Inserm U981, Gustave Roussy Cancer, Université Paris-Saclay, Villejuif, France., Friboulet L; Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Inserm U981, Gustave Roussy Cancer, Université Paris-Saclay, Villejuif, France., Fizazi K; Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Inserm U981, Gustave Roussy Cancer, Université Paris-Saclay, Villejuif, France; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Besse B; Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Inserm U981, Gustave Roussy Cancer, Université Paris-Saclay, Villejuif, France; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Scoazec JY; Experimental and Translational Pathology Platform (PETRA), Genomic Platform - Molecular Biopathology Unit (BMO) and Biological Resource Center, AMMICA, INSERM, Villejuif, France; Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France., Loriot Y; Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Inserm U981, Gustave Roussy Cancer, Université Paris-Saclay, Villejuif, France; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: yohann.loriot@gustaveroussy.fr.
Publikováno v:
European urology oncology [Eur Urol Oncol] 2024 Jun; Vol. 7 (3), pp. 527-536. Date of Electronic Publication: 2023 Oct 27.
Autor:
Menssouri N; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France., Poiraudeau L; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France., Helissey C; Hôpital d'Instruction des Armées BÉGIN, Saint Mandé, France., Bigot L; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France., Sabio J; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France., Ibrahim T; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France., Pobel C; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France., Nicotra C; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France., Ngo-Camus M; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France., Lacroix L; Experimental and Translational Pathology Platform (PETRA), Genomic Platform-Molecular Biopathology Unit (BMO) and Biological Resource Center, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, Villejuif, France.; Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France., Rouleau E; Experimental and Translational Pathology Platform (PETRA), Genomic Platform-Molecular Biopathology Unit (BMO) and Biological Resource Center, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, Villejuif, France.; Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France., Tselikas L; Department of Interventional Radiology, Gustave Roussy Cancer Campus, Villejuif, France., Chauchereau A; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France., Blanc-Durand F; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Bernard-Tessier A; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Patrikidou A; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Naoun N; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Flippot R; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Colomba E; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Fuerea A; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Albiges L; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Lavaud P; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., van de Wiel P; InnoSIGN, High Tech Campus 11, Eindhoven, the Netherlands., den Biezen E; InnoSIGN, High Tech Campus 11, Eindhoven, the Netherlands., Wesseling-Rozendaal Y; InnoSIGN, High Tech Campus 11, Eindhoven, the Netherlands., Ponce S; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France., Michiels S; Oncostat U1018, Inserm, University of Paris-Saclay, Labelled Ligue Contre le Cancer, Villejuif, France., Massard C; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France., Gautheret D; Department of Biostatistics and Epidemiology, Gustave Roussy, University of Paris-Saclay, Villejuif, France.; PRISM Center for Personalized Medicine, Gustave Roussy Cancer Campus, Villejuif, France., Barlesi F; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France., André F; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France.; Department of Biostatistics and Epidemiology, Gustave Roussy, University of Paris-Saclay, Villejuif, France.; PRISM Center for Personalized Medicine, Gustave Roussy Cancer Campus, Villejuif, France., Besse B; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France.; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.; Department of Biostatistics and Epidemiology, Gustave Roussy, University of Paris-Saclay, Villejuif, France., Scoazec JY; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France.; Experimental and Translational Pathology Platform (PETRA), Genomic Platform-Molecular Biopathology Unit (BMO) and Biological Resource Center, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, Villejuif, France.; Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France., Friboulet L; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France., Fizazi K; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France.; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Loriot Y; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France.; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.; Department of Biostatistics and Epidemiology, Gustave Roussy, University of Paris-Saclay, Villejuif, France.; PRISM Center for Personalized Medicine, Gustave Roussy Cancer Campus, Villejuif, France.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Nov 01; Vol. 29 (21), pp. 4504-4517.
Autor:
Colomba E; Gustave Roussy, Université Paris-Saclay, Oncology Medicine Department, Villejuif, F-94805, France., Marret G; Department of Medical Oncology, Hôpital Européen Georges Pompidou, AP-HP, Paris, France., Baciarello G; Gustave Roussy, Université Paris-Saclay, Oncology Medicine Department, Villejuif, F-94805, France., Lavaud P; Gustave Roussy, Université Paris-Saclay, Oncology Medicine Department, Villejuif, F-94805, France., Massard C; Gustave Roussy, Université Paris-Saclay, Oncology Medicine Department, Villejuif, F-94805, France., Loriot Y; Gustave Roussy, Université Paris-Saclay, Oncology Medicine Department, Villejuif, F-94805, France., Albiges L; Gustave Roussy, Université Paris-Saclay, Oncology Medicine Department, Villejuif, F-94805, France., Carton E; Department of Medical Oncology, Hopital Cochin, AP-HP, Paris, France; Université Paris Descartes, Paris, France., Alexandre J; Department of Medical Oncology, Hopital Cochin, AP-HP, Paris, France; Université Paris Descartes, Paris, France., Huillard O; Department of Medical Oncology, Hopital Cochin, AP-HP, Paris, France; Université Paris Descartes, Paris, France., Culine S; Department of Medical Oncology, Hopital Saint Louis APHP, Paris, France., Fizazi K; Gustave Roussy, Université Paris-Saclay, Oncology Medicine Department, Villejuif, F-94805, France. Electronic address: Karim.Fizazi@gustaveroussy.fr.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Apr; Vol. 129, pp. 117-122. Date of Electronic Publication: 2020 Mar 06.
Autor:
Lavaud P; Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France., Gravis G; Institut Paoli Calmette, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Marseille University, UM 105, F-13284, Marseille, France., Foulon S; Department of Clinical Research and Investigation, Biostatistics and Methodology Unit, Institut Gustave Roussy, Villejuif, France., Joly F; Oncology Department, Centre François Baclesse, Caen, France., Oudard S; Oncology Department, European Georges Pompidou Hospital, René Descartes University, Paris, France., Priou F; Department of Oncology, Centre hospitalier départemental Les Oudairies, La Roche-sur-Yon, France., Latorzeff I; Department of Radiotherapy, Groupe ONCORAD Garonne and Clinique Pasteur, Toulouse, France., Mourey L; Department of Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France., Soulié M; Department of Urology, Andrology and Transplantation, Centre Hospitalier Universitaire Toulouse-Rangueil, Toulouse, France., Delva R; Department of Medical Oncology, Paul Papin Cancer Centre, Angers, France., Krakowski I; Department of Oncology, Centre Bergonié, Bordeaux, France., Laguerre B; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France., Théodore C; Department of Medical Oncology, Hopital Foch, Suresnes, France., Ferrero JM; Department of Medical Oncology, Antoine Lacassagne Cancer Centre, Nice, France., Beuzeboc P; Department of Medical Oncology, Curie Institute, Paris, France., Habibian M; R&D Unicancer, Paris, France., Rolland F; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Saint Herblain, France., Deplanque G; Department of Medical Oncology, Hopital Riviera-Chablais, Vaud-Valais - Vevey, Switzerland., Pouessel D; Department of Medical Oncology, Institut Claudius Rigaud, Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France., Zanetta S; Medical Oncology Department, Centre Georges-François Leclerc, Dijon, France., Berdah JF; Medical Oncology Department, Clinique Sainte Marguerite, Hyeres, France., Dauba J; Medical Oncology Department, Hôpital Layné, Mont de Marsan, France., Baciuchka M; Medical Oncology Department, Centre Hospitalier La Timone, Marseille, France., Platini C; Medical Oncology Department, Centre Régional Hospitalier, Metz-Thionville, France., Linassier C; Medical Oncology Department, Hôpital Bretonneau, Tours, France., Tubiana-Mathieu N; Medical Oncology Department, Centre Hospitalier Dupuytren, Limoges, France., Machiels JP; Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Brussels, Belgium., Kouri CE; Medical Oncology Department, Centre Catherine de Sienne, Nantes, France., Ravaud A; Medical Oncology Department, Hôpital Saint-André, Bordeaux, France., Suc E; Medical Oncology Department, Clinique Saint-Jean Languedoc, Toulouse, France., Eymard JC; Medical Oncology Department, Institut Jean Godinot, Reims, France., Hasbini A; Medical Oncology Department, Clinique Armoricaine de Radiologie, Saint Brieuc, France., Bousquet G; Medical Oncology Department, Hôpital Avicenne, Bobigny, France., Culine S; Medical Oncology Department, Hôpital Saint Louis, Paris, France., Boher JM; Department of Clinical Research and Investigation, Biostatistics, and Methodology Unit, Institut Paoli Calmettes, Marseille, France., Tergemina-Clain G; Department of Clinical Research and Investigation, Biostatistics and Methodology Unit, Institut Gustave Roussy, Villejuif, France., Legoupil C; Department of Clinical Research and Investigation, Biostatistics and Methodology Unit, Institut Gustave Roussy, Villejuif, France., Fizazi K; Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Electronic address: karim.fizazi@gustaveroussy.fr.
Publikováno v:
European urology [Eur Urol] 2018 May; Vol. 73 (5), pp. 696-703. Date of Electronic Publication: 2017 Oct 23.
Autor:
Cabel L; Institut Gustave Roussy, University of Paris-Sud, Department of Cancer Medicine, 114 Rue Edouard Vaillant, 94800 Villejuif, France., Loir E; Institut Paoli-Calmettes, Department of Medical Oncology, 13009 Marseille, France., Gravis G; Institut Paoli-Calmettes, Department of Medical Oncology, 13009 Marseille, France., Lavaud P; Institut Gustave Roussy, University of Paris-Sud, Department of Cancer Medicine, 114 Rue Edouard Vaillant, 94800 Villejuif, France., Massard C; Institut Gustave Roussy, University of Paris-Sud, Department of Cancer Medicine, 114 Rue Edouard Vaillant, 94800 Villejuif, France., Albiges L; Institut Gustave Roussy, University of Paris-Sud, Department of Cancer Medicine, 114 Rue Edouard Vaillant, 94800 Villejuif, France., Baciarello G; Institut Gustave Roussy, University of Paris-Sud, Department of Cancer Medicine, 114 Rue Edouard Vaillant, 94800 Villejuif, France., Loriot Y; Institut Gustave Roussy, University of Paris-Sud, Department of Cancer Medicine, 114 Rue Edouard Vaillant, 94800 Villejuif, France., Fizazi K; Institut Gustave Roussy, University of Paris-Sud, Department of Cancer Medicine, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2017 Apr 18; Vol. 5, pp. 31. Date of Electronic Publication: 2017 Apr 18 (Print Publication: 2017).